Literature DB >> 25966742

Ginsenoside rh2 inhibits cancer stem-like cells in skin squamous cell carcinoma.

Shunli Liu1, Mingrui Chen, Pengcheng Li, Yujia Wu, Chunjuan Chang, Yabin Qiu, Ling Cao, Zhen Liu, Chiyu Jia.   

Abstract

BACKGROUND/AIMS: Treatments targeting cancer stem cells (CSCs) are most effective cancer therapy, whereas determination of CSCs is challenging. We have recently reported that Lgr5-positive cells are cancer stem cells (CSCs) in human skin squamous cell carcinoma (SCC). Ginsenoside Rh2 (GRh2) has been shown to significantly inhibit growth of some types of cancers, whereas its effects on the SCC have not been examined.
METHODS: Here, we transduced human SCC cells with lentivirus carrying GFP reporter under Lgr5 promoter. The transduced SCC cells were treated with different doses of GRh2, and then analyzed cell viability by CCK-8 assay and MTT assay. The effects of GRh2 on Lgr5-positive CSCs were determined by fow cytometry and by tumor sphere formation. Autophagy-associated protein and β-catenin were measured by Western blot. Expression of short hairpin small interfering RNA (shRNA) for Atg7 and β-catenin were used to inhibit autophagy and β-catenin signaling pathway, respectively, as loss-of-function experiments.
RESULTS: We found that GRh2 dose-dependently reduced SCC viability, possibly through reduced the number of Lgr5-positive CSCs. GRh2 increased autophagy and reduced β-catenin signaling in SCC cells. Inhibition of autophagy abolished the effects of GRh2 on β-catenin and cell viability, while increasing β-catenin abolished the effects of GRh2 on autophagy and cell viability.
CONCLUSION: Taken together, our data suggest that GRh2 inhibited SCC growth, possibly through reduced the number of Lgr5-positive CSCs. This may be conducted through an interaction between autophagy and β-catenin signaling.
© 2015 S. Karger AG, Basel.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25966742     DOI: 10.1159/000430115

Source DB:  PubMed          Journal:  Cell Physiol Biochem        ISSN: 1015-8987


  20 in total

1.  Enhanced Wnt signaling by methylation-mediated loss of SFRP2 promotes osteosarcoma cell invasion.

Authors:  Qiang Xiao; Yu Yang; Xuepu Zhang; Qing An
Journal:  Tumour Biol       Date:  2015-12-01

2.  Ginsenoside Rh2 inhibits prostate cancer cell growth through suppression of microRNA-4295 that activates CDKN1A.

Authors:  Qiruo Gao; Junhua Zheng
Journal:  Cell Prolif       Date:  2018-02-19       Impact factor: 6.831

3.  Paving the Road Toward Exploiting the Therapeutic Effects of Ginsenosides: An Emphasis on Autophagy and Endoplasmic Reticulum Stress.

Authors:  Milad Ashrafizadeh; Shima Tavakol; Reza Mohammadinejad; Zahra Ahmadi; Habib Yaribeygi; Tannaz Jamialahmadi; Thomas P Johnston; Amirhossein Sahebkar
Journal:  Adv Exp Med Biol       Date:  2021       Impact factor: 2.622

4.  TIPE2 regulates tumor-associated macrophages in skin squamous cell carcinoma.

Authors:  Xin Li
Journal:  Tumour Biol       Date:  2015-11-15

5.  Methylation-mediated loss of SFRP2 enhances melanoma cell invasion via Wnt signaling.

Authors:  Xiaoji Luo; Bin Wei; Aijun Chen; Hengguang Zhao; Kun Huang; Jin Chen
Journal:  Am J Transl Res       Date:  2016-03-15       Impact factor: 4.060

6.  Ginsenoside Rh2 inhibiting HCT116 colon cancer cell proliferation through blocking PDZ-binding kinase/T-LAK cell-originated protein kinase.

Authors:  Jianjun Yang; Donghong Yuan; Tongchao Xing; Hongli Su; Shengjun Zhang; Jiansheng Wen; Qiqiang Bai; Dongmei Dang
Journal:  J Ginseng Res       Date:  2016-04-05       Impact factor: 6.060

7.  Defective autophagy leads to the suppression of stem-like features of CD271+ osteosarcoma cells.

Authors:  Dong Zhang; Qing Zhao; Hao Sun; Lijuan Yin; Jiajun Wu; Jun Xu; Tianxiang He; Chunlei Yang; Chengwei Liang
Journal:  J Biomed Sci       Date:  2016-11-18       Impact factor: 8.410

8.  Comparative analysis of the expression level of recombinant ginsenoside-transforming β-glucosidase in GRAS hosts and mass production of the ginsenoside Rh2-Mix.

Authors:  Muhammad Zubair Siddiqi; Chang-Hao Cui; Seul-Ki Park; Nam Soo Han; Sun-Chang Kim; Wan-Taek Im
Journal:  PLoS One       Date:  2017-04-19       Impact factor: 3.240

Review 9.  Anticancer Activities of Protopanaxadiol- and Protopanaxatriol-Type Ginsenosides and Their Metabolites.

Authors:  Xiao-Jia Chen; Xiao-Jing Zhang; Yan-Mei Shui; Jian-Bo Wan; Jian-Li Gao
Journal:  Evid Based Complement Alternat Med       Date:  2016-06-30       Impact factor: 2.629

10.  New generation of drug delivery systems based on ginsenoside Rh2-, Lysine- and Arginine-treated highly porous graphene for improving anticancer activity.

Authors:  Hadi Zare-Zardini; Asghar Taheri-Kafrani; Ahmad Amiri; Abdol-Khalegh Bordbar
Journal:  Sci Rep       Date:  2018-01-12       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.